Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma

Abstract. Background:. The isatuximab, pomalidomide, and dexamethasone (Isa-Pd) regimen has shown survival benefits for relapsed and/or refractory multiple myeloma (RRMM) in several trials, while evidence of effectiveness and safety among Chinese patients is limited. This study aimed to provide rea...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Wenting Chen, Jianhua You, Li’e Lin, Xiaojing Yan, Gang An, Yafei Wang, Weiwei Tian, Kaiyang Ding, Xi Zhang, Wenming Chen, Yingxue Wang, Baijun Fang, Jing Liu, Weilin Xia, Zhaoyi Feng, Lei Zhou, Zhini Wang, Dan Shen, Gang Liu, Weili Zhao, Sihan Zhou, Xiuyuan Hao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wolters Kluwer 2026-02-01
coleção:	Chinese Medical Journal
Acesso em linha:	http://journals.lww.com/10.1097/CM9.0000000000003649
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!